Ann Thorac Surg 2005;79:782-783
© 2005 The Society of Thoracic Surgeons
INVITED COMMENTARY
Alfred Nicolosi, MD
Department of Cardiothoracic Surgery, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, 9200 W Wisconsin Ave, Milwaukee, WI 53226-0099
(E-mail: nicolosi@mcw.edu).
| The first 20% of the full text of this article appears below. |
This article by Emery and colleagues represents a unique experience by a premier surgical group. As noted by the authors, inherent thrombogenicity of the prosthesis and the resultant need for anticoagulation remain the major causes of valve-related events in these patients. At 15 years, the cumulative incidences of thromboembolic and hemorrhagic events reach 15% and 21%, respectively with aortic replacements and they reach 20% and 20%, respectively with mitral valve replacements. These values are important, as . . . [Full Text of this Article]
Related Article
-
The St. Jude Medical Cardiac Valve Prosthesis: A 25-Year Experience With Single Valve Replacement
- Robert W. Emery, Christopher C. Krogh, Kit V. Arom, Ann M. Emery, Kathy Benyo-Albrecht, Lyle D. Joyce, and Demetre M. Nicoloff
Ann. Thorac. Surg. 2005 79: 776-782.
[Abstract]
[Full Text]
[PDF]
Copyright © 2005 by The Society of Thoracic Surgeons.